GuidelineAnnals of the rheumatic diseases2018
First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL,
Guideline in Annals of the rheumatic diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Saudi National Clinical Practice Guidelines for Management of Adult Systemic Lupus Erythematosus.Current rheumatology reviews · 2025Guideline
- Denosumab, teriparatide and bisphosphonates for glucocorticoid-induced osteoporosis: a Bayesian network meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Chinese Herbal Medicine for Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized, Placebo-Controlled Trials.Chinese journal of integrative medicine · 2021Pooled it
- Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2-3 mg/kg/day): 12-month prospective randomized controlled trial.Clinical rheumatology · 2021Trial
- Towards a global collaborative approach to living guideline development in rheumatology.Nature reviews. Rheumatology · 2026Article
- Demographic and clinical characteristics of patients with systemic lupus erythematosus across five registries: the LupusNet federated data network.Lupus science & medicine · 2026Article
- Review
- Living with systemic lupus erythematosus in 2024: Latin American experience based on a patient survey.Clinical rheumatology · 2026Article
- Low-dose rituximab for MPO-ANCA-associated hypertrophic pachymeningitis with delayed onset of renal involvement: a case report.Frontiers in medicine · 2026Article
- Factors influencing the choice of non-biologic versus biologic immunosuppressive therapy in systemic lupus erythematosus.Scientific reports · 2025Article
- Prediction model for renal outcomes in Latin American Mestizo patients with pure proliferative lupus nephritis.Lupus science & medicine · 2025Article
- Recommendations for the Use of Disease-Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review.Arthritis care & research · 2025Article
- Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus.Nature reviews. Rheumatology · 2025Review
- Systematic Review and Network Meta-Analysis of Initial Treatments for Lupus Nephritis.Kidney international reports · 2025Article
- The Lupus Check 5 Tool: A Practical Approach to Initiating Treatment Reviews in Systemic Lupus Erythematosus.Rheumatology and therapy · 2025Article
- Item-specific factors associated with damage accrual in systemic lupus erythematosus: insights from a multiethnic, multinational Latin American cohort.Lupus science & medicine · 2025Article
- Treatment of thrombotic microangiopathy associated with systemic lupus erythematosus with low-dose rituximab as an induction agent and belimumab as a maintenance agent.BMC pediatrics · 2025Article
- The novel diagnostic markers for systemic lupus erythematosus and periodontal disease.Frontiers in immunology · 2025Article
- The Potential of Telitacicept in Treating Lupus erythematosus panniculitis: A Case Report.Biologics : targets & therapy · 2025Article
- Treatment trends of systemic lupus erythematosus from 2007 to 2023 in the USA.Lupus science & medicine · 2024Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
96 authors at 20 institutions in 12 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.